Louisiana State Employees Retirement System Purchases Shares of 15,800 LivaNova PLC $LIVN

Louisiana State Employees Retirement System purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN) in the first quarter, according to its most recent filing with the SEC. The firm purchased 15,800 shares of the company’s stock, valued at approximately $1,004,000.

Other hedge funds have also recently made changes to their positions in the company. SG Americas Securities LLC boosted its position in shares of LivaNova by 256.6% during the 1st quarter. SG Americas Securities LLC now owns 86,490 shares of the company’s stock valued at $5,497,000 after purchasing an additional 62,233 shares in the last quarter. Diversified Trust Co lifted its stake in LivaNova by 12.3% in the first quarter. Diversified Trust Co now owns 21,028 shares of the company’s stock valued at $1,337,000 after buying an additional 2,303 shares during the period. Hsbc Holdings PLC boosted its holdings in shares of LivaNova by 260.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,301 shares of the company’s stock worth $1,255,000 after buying an additional 14,671 shares in the last quarter. Corient Private Wealth LLC acquired a new stake in shares of LivaNova during the 4th quarter worth approximately $302,000. Finally, Pacer Advisors Inc. grew its position in shares of LivaNova by 131.7% during the 4th quarter. Pacer Advisors Inc. now owns 16,661 shares of the company’s stock worth $1,025,000 after buying an additional 9,471 shares during the period. 97.64% of the stock is owned by institutional investors.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $83.62 on Friday. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. LivaNova PLC has a twelve month low of $41.01 and a twelve month high of $83.98. The stock’s 50 day moving average is $73.95 and its 200-day moving average is $67.62. The firm has a market capitalization of $4.59 billion, a price-to-earnings ratio of 42.88 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.13. The business had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. LivaNova’s revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Sell-side analysts forecast that LivaNova PLC will post 3.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LIVN has been the topic of a number of research reports. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Barclays raised their price target on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Robert W. Baird decreased their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. KeyCorp increased their price objective on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, June 22nd. Finally, Mizuho increased their price objective on shares of LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.75.

Insider Activity

In other news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the sale, the director directly owned 7,228 shares of the company’s stock, valued at $547,521. The trade was a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.35% of the stock is owned by corporate insiders.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.